社区获得性肺炎患者血清 HBD-1、SAA、 sIL-2R水平变化及指导病情分级的意义.

Objective To measure the levels of serum human beta-defensin-1 (HBD-1), serum amyloid A (SAA), and soluble interleukin-2 receptor (SIL-2R) in patients with community-acquired pneumonia (CAP) and to analyze their significance in guiding disease severity classification. Methods From July 2021 to August 2023,85 CAP patients (the CAP group) treated at the hospital were selected and categorized into the low-risk (34 cases), the moderate-risk (41 cases), and the high-risk (10 cases) groups based on the Pneumonia Severity Index (PSI). Another 85 healthy adults were included as a control group. The levels of serum HBD-1, SAA, and sIL-2R in the CAP group and the control group were compared, as well as among different PSI risk categories. Receiver operating characteristic (ROC) curve analysis was used to evaluate the diagnostic value of HBD-1, SAA, and sIL-2R levels for CAP patients. Spearman correlation analysis was applied to assess the re- lationship between PSI scores and the levels of serum HBD-1, SAA, and sIL-2R in CAP patients. Results Levels of serum HBD-1, SAA, and sIL-2R in the CAP patients were higher than those in the control group. Among the PSI categories, levels decreased from the high-risk to low-risk groups with significant differences (P< 0.05). ROC analysis indicated that serum levels of HBD-1 (AUC = 0.739), SAA (AUC = 0.773), and sIL-2R (AUC = 0.73) had good diagnostic value for the CAP patients (P < 0.05) Spearman correlation analysis showed positive correlations between PSI scores and levels of HBD-1 [correlation coefficient (r) = 0.304 ] SAA (r = 0.498), and sIL-2R (r = 0.435) (P < 0.05) Conclusion Serum levels of HBD-1.SAA. and SIL-2R have significant guidance value in the severity classification of CAP patients. [ABSTRACT FROM AUTHOR]